Can-Fite BioPharma (CANF) Receivables - Net (2013 - 2021)

Can-Fite BioPharma's (CANF) quarterly Receivables - Net came in at $3.6 million in Q2 2020, down 18.62% on a QoQ basis from $4.4 million in Q4 2019.

Can-Fite BioPharma (CANF) Receivables - Net (2013 - 2021) Analysis & Trends

Can-Fite BioPharma (CANF) has 6 years of Receivables - Net data on file, last reported at $3.6 million in Q2 2020.

Quarterly Receivables - Net changed N/A year-over-year to $3.6 million in Q2 2020, while the trailing twelve-month figure through Jun 2020 was $3.6 million (changed N/A YoY) and the FY2019 annual result came in at $4.4 million, up 9.17% from the prior year.
Receivables - Net eased to $3.6 million in Q2 2020, from $4.4 million in the prior quarter.
In the past five years, Receivables - Net ranged from a high of $4.4 million in Q4 2019 to a low of $3.6 million in Q2 2020.
A 3-year average of $4.0 million and a median of $4.0 million in 2018 frame the typical range for Receivables - Net.
The widest YoY moves for Receivables - Net: up 9.17% in 2019, down 9.17% in 2019.
Tracing CANF's Receivables - Net over 3 years: stood at $4.0 million in 2018, then grew by 9.17% to $4.4 million in 2019, then slipped by 18.62% to $3.6 million in 2020.
The last three Receivables - Net figures came in at $3.6 million (Q2 2020), $4.4 million (Q4 2019), and $4.0 million (Q4 2018), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Can-Fite BioPharma	2.82 Mn	-8.73 Mn	-

Download Data